F furthermore, impedance to imatinib mesylate, a tyrosine kinase inhibitor used in the chronic stage of CML intervention, was associated with increased AQP5 expression. This evidence concerns the gene AQP5 and chronic myelogenous leukemia, BCR-ABL1 positive.